oxandrolone has been researched along with Weight Reduction in 18 studies
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of oxandrolone in promoting body weight and body cell mass (BCM) gain in HIV-associated weight loss." | 9.12 | Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. ( Bhasin, S; Dobs, A; Glesby, M; Grunfeld, C; Kotler, DP, 2006) |
| " In a randomized trial, we compared the effects of 2 months of treatment with either megestrol acetate (800 mg every day) or oxandrolone (10 mg twice per day) on body weight and composition in patients with weight loss of > or =5 kg who were receiving HAART." | 9.11 | Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. ( Albrecht, M; Chang, H; Forfia, J; Gerrior, J; Miller, L; Mwamburi, DM; Saboori, S; Scully, E; Wanke, CA; Wilson, IB, 2004) |
| "Oxandrolone is an effective adjunct to facilitate weight restoration in patients with COPD-associated weight loss." | 9.10 | Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. ( DeGuzman, B; Kramer, T; Yeh, SS, 2002) |
| "We studied the effect of an anabolic steroid, oxandrolone, combined with a high-protein diet (2 g/kg/day) on the rate of weight gain and restoration of muscle function in the recovery phase after deep burns of 30 of 50% of total body surface (n = 7)." | 9.08 | Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. ( Demling, RH; DeSanti, L, 1997) |
| "To evaluate the efficacy and safety of oxandrolone in promoting body weight and body cell mass (BCM) gain in HIV-associated weight loss." | 5.12 | Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. ( Bhasin, S; Dobs, A; Glesby, M; Grunfeld, C; Kotler, DP, 2006) |
| " In a randomized trial, we compared the effects of 2 months of treatment with either megestrol acetate (800 mg every day) or oxandrolone (10 mg twice per day) on body weight and composition in patients with weight loss of > or =5 kg who were receiving HAART." | 5.11 | Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. ( Albrecht, M; Chang, H; Forfia, J; Gerrior, J; Miller, L; Mwamburi, DM; Saboori, S; Scully, E; Wanke, CA; Wilson, IB, 2004) |
| "Oxandrolone is an effective adjunct to facilitate weight restoration in patients with COPD-associated weight loss." | 5.10 | Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. ( DeGuzman, B; Kramer, T; Yeh, SS, 2002) |
| "We studied the effect of an anabolic steroid, oxandrolone, combined with a high-protein diet (2 g/kg/day) on the rate of weight gain and restoration of muscle function in the recovery phase after deep burns of 30 of 50% of total body surface (n = 7)." | 5.08 | Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. ( Demling, RH; DeSanti, L, 1997) |
| " Current studies include the effects of protease inhibitors on blood sugar, the effectiveness of twice a day Crixivan dosing, the effectiveness of adefovir dipivoxil in combination with protease inhibitors, the effectiveness of DMP 266 in combination with several drugs, and the effects of Oxandrolone on weight loss in women." | 3.70 | CRIA clinical trials. ( , 1998) |
| "Oxandrolone was well tolerated in all the patients who were enrolled in the study." | 2.68 | Oxandrolone in AIDS-wasting myopathy. ( Berger, JR; Berry, PS; Dudley, R; Hall, CD; Pall, L; Simpson, DM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yeh, SS | 1 |
| DeGuzman, B | 1 |
| Kramer, T | 1 |
| Mwamburi, DM | 1 |
| Gerrior, J | 1 |
| Wilson, IB | 1 |
| Chang, H | 1 |
| Scully, E | 1 |
| Saboori, S | 1 |
| Miller, L | 1 |
| Forfia, J | 1 |
| Albrecht, M | 1 |
| Wanke, CA | 1 |
| James, JS | 1 |
| Grunfeld, C | 1 |
| Kotler, DP | 1 |
| Dobs, A | 1 |
| Glesby, M | 1 |
| Bhasin, S | 1 |
| Berger, JR | 2 |
| Pall, L | 1 |
| Hall, CD | 1 |
| Simpson, DM | 1 |
| Berry, PS | 1 |
| Dudley, R | 1 |
| Demling, RH | 1 |
| DeSanti, L | 1 |
| Kravetz, JD | 1 |
| Lee, C | 1 |
| Dieterich, DT | 1 |
| Demling, R | 1 |
| De Santi, L | 1 |
| Earthman, CP | 1 |
| Matthie, JR | 1 |
| Reid, PM | 1 |
| Harper, IT | 1 |
| Ravussin, E | 1 |
| Howell, WH | 1 |
| Romeyn, M | 1 |
| Gunn, N | 1 |
| Taiwo, BO | 1 |
| Krasner, DL | 1 |
| Belcher, AE | 1 |
| Langer, CJ | 1 |
| Hoffman, JP | 1 |
| Ottery, FD | 1 |
| Yarasheski, KE | 1 |
| Roubenoff, R | 1 |
| Nightingale, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study[NCT01061970] | Phase 2 | 15 participants (Anticipated) | Interventional | 2007-01-31 | Completed | ||
| Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523] | 86 participants (Actual) | Interventional | 2018-08-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for oxandrolone and Weight Reduction
| Article | Year |
|---|---|
HIV-associated wasting: brief review and discussion of the impact of oxandrolone.
Topics: Anabolic Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Approval; Fever; Humans; Muscle We | 2000 |
Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia.
Topics: Anabolic Agents; Appetite Stimulants; Body Weight; Cachexia; HIV Wasting Syndrome; Humans; Neoplasms | 2001 |
Exercise treatment for HIV-associated metabolic and anthropomorphic complications.
Topics: Acquired Immunodeficiency Syndrome; Anabolic Agents; Anthropometry; Antiretroviral Therapy, Highly A | 2001 |
5 trials available for oxandrolone and Weight Reduction
| Article | Year |
|---|---|
Reversal of COPD-associated weight loss using the anabolic agent oxandrolone.
Topics: Aged; Anabolic Agents; Body Composition; Body Weight; Exercise Tolerance; Female; Humans; Karnofsky | 2002 |
Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months.
Topics: Adult; Androgens; Antiretroviral Therapy, Highly Active; Body Weight; Female; HIV Infections; Humans | 2004 |
Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Anabolic Agents; Body Mass Index; Double-Blind Method; Follicle Stimulating Hormone; HIV Infe | 2006 |
Oxandrolone in AIDS-wasting myopathy.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Anabolic Agents; Double-Blind Method; HIV- | 1996 |
Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns.
Topics: Adult; Anabolic Agents; Burns; Dietary Proteins; Energy Intake; Female; Humans; Male; Oxandrolone; P | 1997 |
10 other studies available for oxandrolone and Weight Reduction
| Article | Year |
|---|---|
Involuntary weight loss: interview with Lisa Capaldini, M.D.
Topics: Appetite Stimulants; Body Composition; HIV Wasting Syndrome; Humans; Megestrol Acetate; Oxandrolone; | 2005 |
Oxandrolone use in Crohn's disease.
Topics: Adult; Anabolic Agents; Anti-Inflammatory Agents; Body Mass Index; Crohn Disease; Electric Impedance | 1997 |
Closure of the "non-healing wound" corresponds with correction of weight loss using the anabolic agent oxandrolone.
Topics: Adult; Aged; Aged, 80 and over; Anabolic Agents; Body Weight; Combined Modality Therapy; Debridement | 1998 |
A comparison of bioimpedance methods for detection of body cell mass change in HIV infection.
Topics: Adult; Anabolic Agents; Body Water; Body Weight; Electric Impedance; Evaluation Studies as Topic; Ex | 2000 |
Resistance exercise and oxandrolone for men with HIV-related weight loss.
Topics: Anabolic Agents; Exercise; Female; HIV Infections; HIV Wasting Syndrome; Humans; Male; Oxandrolone; | 2000 |
Resistance exercise and oxandrolone for men with HIV-related weight loss.
Topics: Anabolic Agents; Exercise; HIV Infections; Humans; Male; Muscle Weakness; Oxandrolone; Weight Loss | 2000 |
Oxandrolone restores appetite. An increase in weight helps heal wounds.
Topics: Aged; Anabolic Agents; Anorexia; Appetite; Chronic Disease; Humans; Nursing Assessment; Nutrition As | 2000 |
CRIA clinical trials.
Topics: Adenine; Alkynes; Anabolic Agents; Anti-HIV Agents; Benzoxazines; Blood Glucose; Clinical Trials as | 1998 |
From the Food and Drug Administration.
Topics: Adrenal Cortex Hormones; Antifungal Agents; Atovaquone; Chickenpox; Child; Contraindications; Drug L | 1992 |
Orphan drug for HIV wasting syndrome.
Topics: Anorexia; HIV Infections; Humans; Oxandrolone; Syndrome; Weight Loss | 1991 |